Marseille-Kliniken AG

EANS-News: Annual accounts 2011/2012: Marseille-Kliniken AG improves profitability

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Financial Figures/Balance Sheet

Subtitle: - EBIT with EUR 10.9 million almost doubled
- Group income increases by more than 124% to EUR 6.5 million 
- Occupancy rate increased to 88.9%, but still has potential for improvement
- Internal reorganization shall be continued in order to further strengthen
profitability

Hamburg (euro adhoc) - Marseille-Kliniken AG could significantly improve its
results in business year 2011/2012 (1 July 2011 - 30 June 2012). Based on an
increase in revenues from EUR 190.0 million (2010/2011) to EUR 195.1 million
EBIT increased from EUR 5.7 million (2010/2011) to EUR 10.9 million. With a
change from EUR 2.9 million (2010/2011) to EUR 6.5 million group income
attributable to shareholders improved even stronger. In the course of these
developments also the equity ratio increased from 17.1% (2010/2011) to 19.5%.
"Last business year has demonstrated the success of our strategic reorganization
which has been the basis for the improved earnings and financial power" says
Michael Thanheiser, chairman of Marseille-Kliniken AG.

The turnaround which has already been initiated in the previous business year
has been continued with these results, as the realignment of the group's
strategy is the basis for the improved cost efficiency. The strategy consists of
focusing on the core business nursing care in the segments inpatient and
outpatient, strengthening of quality leadership and initiation of a
decentralized management structure.

As a result of these measures the company achieved improvements on all earnings
figures. Occupancy rate increased by 1.8 percentage points to 88.9% at a sales
capacity of 7,915 beds. Revenue thereby increased by 2.7% to EUR 195.1 million.
EBITDAR increased by 5.6% to EUR 54.8 million, EBITDA by 28.5% to EUR 17.6
million and EBIT by 91.2% to EUR 10.9 million. EBIT margin correspondingly
improved by 2.6 percentage points to 5.6%. Group income attributable to
shareholders increased by 124% to EUR 6.5 million which causes earnings per
share of EUR 0.45 (previous year: EUR 0.20) based on the 14.46 million
outstanding shares. Reasons for this disproportionately large development were
low taxes on income and an almost constant financial result. Extraordinary items
balanced to EUR -0.8 million caused only a minor effect on the financial
accounts.

Operational improvements in business year 2011/2012 were in particular achieved
at facilities which previously had a capacity utilization below average. By
targeted measures the occupancy rates could be increased at these locations.
With the improvements realized in bed occupancy rate the company however has an
average vacancy rate of more than 10%. Further improvements in this respect will
access a potential on profitability in the future. The general skills shortage
in Germany thereby hinders the company from rapidly improving capacity
utilization. Therefore specific measures for recruitment of new and binding of
existing personnel have been initiated.

The group has recently expanded its management capacities, as firstly the
contract with chairman Michael Thanheiser was prolonged until 31 March 2017 and
secondly with Dieter Wopen another member of the management board was newly
appointed starting on 15 November 2012.

Michael Thanheiser comments the existing figures as follows: "We are pleased
with the achieved results as they correspond with our previously announced
expectations. Also the current situation in our company's operational business
confirms our ambition to achieve continued and sustainable increases in earnings
for the future. I am looking forward for the future collaboration with Dieter
Wopen, as his appointment will further strengthen our competencies for the
nursing care business on management level. We will particularly focus on the
reduction of vacancies and staffing issues against the background of the
existing skills shortage in the German healthcare sector."

For the current business year 2012/2013 Marseille-Kliniken AG expects an
increase in EBIT and revenues slightly above previous year's level.

The complete annual report 2011/2012 such as additional shareholders'
information is available for the public in the investor relations section of the
company's website at www.marseille-kliniken.com.

-- End of corporate news --

About Marseille-Kliniken AG:

Marseille-Kliniken AG (ISIN DE0007783003, WKN 778300, MKA) with its 57
residential care facilities, three residential units for assisted living and
about 4,700 employees is a market leading listed company on health care in
Germany. The business model is significantly influenced by the demographic
development. Therefore Marseille-Kliniken AG has a secured future. Short-term
economic fluctuations on the other hand exert only a minor influence. As a
consistently modern company with strong focus on quality, the private enterprise
is in a good position within a competitive environment primarily characterized
by regionally active charities.


Further inquiry note:
Hillermann Consulting
Jan Pahl
Investor Relations for Marseille-Kliniken AG
Poststraße 14-16
20354 Hamburg
Germany
Tel.: +49-(0)40 / 3202791-0
www.marseille-kliniken.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     Marseille-Kliniken AG
             Alte Jakobstraße 79/80
             D-10179 Berlin
phone:       +49 (0)30 246 32-400
FAX:         +49 (0)30 246 32-401
mail:     info@marseille-kliniken.de
WWW:      http://www.marseille-kliniken.de
sector:      Pharmaceuticals
ISIN:        DE0007783003
indexes:     CDAX, Classic All Share, Prime All Share
stockmarkets: free trade: Berlin, Düsseldorf, Stuttgart, regulated dealing:
             Hamburg, regulated dealing/prime standard: Frankfurt 
language:   English
 



Weitere Meldungen: Marseille-Kliniken AG

Das könnte Sie auch interessieren: